| Trial ID: | L3176 |
| Source ID: | NCT06589765
|
| Associated Drug: |
Hrs-7535 Tablet
|
| Title: |
A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: HRS-7535 tablet|DRUG: dapagliflozin tablet
|
| Outcome Measures: |
Primary: Change from baseline in HbA1c at 32 weeks of treatment, at 32 weeks | Secondary: Percentage of Participants Who Achieved HbA1c <7.0% at Week 32, at 32 weeks|Percentage of Participants Who Achieved HbA1c ≤6.5% at Week 32, at 32 weeks|Change from Baseline in Fasting Serum Glucose, from Baseline to Week 32, at 32 weeks|Percentage Change from Baseline in Body Weight, from Baseline to Week 32, at 32 weeks|Change from Baseline in Body Weight, from Baseline to Week 32, at 32 weeks|Change from Baseline in Waist Circumference, from Baseline to Week 32, at 32 weeks
|
| Sponsor/Collaborators: |
Sponsor: Shandong Suncadia Medicine Co., Ltd.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
800
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2024-09-27
|
| Completion Date: |
2026-07-18
|
| Results First Posted: |
|
| Last Update Posted: |
2025-01-09
|
| Locations: |
Beijing Hospital, Beijing, Beijing, 100730, China
|
| URL: |
https://clinicaltrials.gov/show/NCT06589765
|
